Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NovoSeven in cirrhotic patients undergoing partial hepatectomy
NCT01562821Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Jul 2001
- Primary completion
- Dec 2002
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of coagulation factor VIIa in acquired bleeding disorder (3 arms), sponsored by Novo Nordisk. Primary endpoint: Red Blood Cell transfusion requirements. Started Jul 2001; status: completed.
02
Drugs
coagulation factor VIIa
03
Conditions
acquired bleeding disorder
Beyond the preview
Go deeper on NCT01562821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01562821.